We serve Chemical Name:(4-(trifluoromethyl)pyridin-2-yl)methanamine CAS:872577-05-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:(4-(trifluoromethyl)pyridin-2-yl)methanamine
CAS.NO:872577-05-4
Synonyms:2-Amino-5,6-dimethyl-4-(1H-pyrrol-2-yl)nicotinonitrile;C-(4-trifluoromethylpyridin-2yl)methylamine;1-(4-(trifluoromethyl)pyridin-2-yl)methanamine;(4-(trifluoromethyl)pyridin-2-yl)methanamine;3-Pyridinecarbonitrile, 2-amino-5,6-dimethyl-4-(1H-pyrrol-2-yl)-;(4-Trifluoromethylpyridin-2-yl)methylamine
Molecular Formula:C12H12N4
Molecular Weight:212.251
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:464.5±45.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.641
PSA:38.91000
Exact Mass:212.106201
LogP:2.54
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 2-Amino-5,6-dimethyl-4-(1H-pyrrol-2-yl)nicotinonitrile chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-Trifluoromethylpyridin-2-yl)methylamine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,C-(4-trifluoromethylpyridin-2yl)methylamine Use and application,3-Pyridinecarbonitrile, 2-amino-5,6-dimethyl-4-(1H-pyrrol-2-yl)- technical grade,usp/ep/jp grade.
Related News: The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. (4-(trifluoromethyl)pyridin-2-yl)methanamine manufacturer In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. (4-(trifluoromethyl)pyridin-2-yl)methanamine supplier In recent years, with the increasing number of patent medicines whose patents have expired, the variety and quantity of generic drugs have also increased rapidly, which has brought huge market opportunities to the API market and the output of APIs has continued to increase. (4-(trifluoromethyl)pyridin-2-yl)methanamine vendor The foundational patent, which expires in 2034, is owned by MSK and is licensed exclusively to Fate Therapeutics for all human therapeutic uses. (4-(trifluoromethyl)pyridin-2-yl)methanamine factory Taiwan previously participated as an observer at the World Health Assembly, the W.H.O.��s governing body.
